Human biological samples · FFPE tissue

FFPE tissue for oncology research: blocks, slides, curls and control tissue

Source FFPE tumor blocks, unstained FFPE slides, FFPE tissue sections and curls with linked clinical and molecular data. Select primary tumors, metastases or normal tissue around your indication, treatment history and biomarker requirements. Tissue, format and data availability are reviewed for your cohort. Add IHC or RNAscope to your tissue request and work with one point of contact, from case selection through staining and pathologist scoring.
GCLP-accredited laboratories · ISO 9001 certified

Archived tissue cassettes arranged in a laboratory
FFPE tissue · Translational research

HBS & DONOR DATA

Quality biospecimens & data for precision medicine

Tissue for your cohort

Select the tissue type around your indication and study requirements.

Primary tumors

Tissue from the primary tumor site.

Metastases

Metastatic tissue, including matched primary and distant metastases in selected collections. Matched tumor and normal tissue is available in selected collections.

Normal tissue

Non-malignant tissue, including matched normal samples in selected collections.

Tissue types and donor matching vary by collection. Explore cohorts by indication

FFPE samples for your workflow

Work with our team to define the preparation and quantity your assay requires.

FFPE tissue blocks

Paraffin-embedded tissue for preparing sections or curls.

Unstained sections

Unstained FFPE slides: thin sections mounted on glass slides, with slide preparation, thickness and count agreed for your study.

FFPE curls and scrolls

Unmounted sections, with thickness, quantity and collection requirements agreed for your workflow.

For FFPE tissue procurement, specify the indication, tissue type, format and quantity, then identify the clinical or molecular records essential to your study. Our team reviews case-level feasibility and confirms preparation against available tissue. Existing records and any additional testing are scoped separately.

UK · Italy · France · GCLP-accredited laboratories · ISO 9001 certified

Donors from participating medical centers, with informed consent and ethics approval.

Breadth of donor profiles

Specimen, treatment, outcomes and molecular data, structured at the patient level.

Patient trajectory

  • Primary tumors & matched distant metastases
  • Matched normal tissue
  • Neoadjuvant & adjuvant treatment
  • Standard-of-care targeted therapies & checkpoint inhibitors
  • Treatment regimen, line & dates
  • Responders & non-responders

Structured outcomes

  • Clinician-recorded response
  • Overall survival (months)
  • Progression-free survival (months)
  • Time to events (months)
  • Last follow-up
  • Event flags: recurrence / death / composite

Molecular characterization

  • IHC
  • FISH
  • RNA-ISH
  • NGS: SNVs, CNVs & fusions

Records are fully anonymized. Available fields vary by donor and reflect clinical practice at the source center. Cohorts are selected to meet your project’s requirements.

FFPE TISSUE COHORTS

Available FFPE cohorts

Explore 112 FFPE cohorts by tissue type, biomarker and treatment history. Find samples with the clinical and molecular data your study needs.

Colorectal cancer

Colorectal cancer cohorts with mutation, HER2, MSI, treatment, metastasis or matched-plasma data, plus colon adenoma.

12FFPE
cohorts

62TMAs

Explore Colorectal cancer cohorts

Lung cancer

NSCLC cohorts with histopathology, EGFR/KRAS, PD-L1, treatment, matching or optional datasets.

19FFPE
cohorts

53TMAs

Explore Lung cancer cohorts

Melanoma

Melanoma cohorts with treatment and follow-up information, including explicitly unmatched pre/post-treatment groups.

6FFPE
cohorts

15TMAs

Explore Melanoma cohorts

Ovarian cancer

Ovarian cohorts with serous histology, platinum-treatment information, selected BRCA status or matched plasma.

6FFPE
cohorts

18TMAs

Explore Ovarian cancer cohorts
Explore tissue and patient profiles

Find tissue around your diagnosis, biomarker and treatment criteria. Our team can help define the cohort for your study.

NSCLC · Patient profile

EGFR-mutated locally advanced or metastatic disease

NSCLC · Patient profile

EGFR-mutated, MET-positive locally advanced or metastatic disease

NSCLC · Patient profile

EGFR exon 20 insertion mutation

NSCLC · Patient profile

TKI-treatment-naïve ROS1-positive disease

NSCLC · Patient profile

Advanced or metastatic NSCLC

NSCLC · Patient profile

PD-L1 <50% metastatic NSCLC

NSCLC · Patient profile

PD-L1 tumor-cell expression ≥1% non-squamous NSCLC

NSCLC · Patient profile

PD-L1 tumor-cell expression ≥1% squamous NSCLC

NSCLC · Patient profile

PD-L1 tumor-cell expression ≥50% locally advanced or metastatic non-squamous NSCLC

NSCLC · Patient profile

Before or after immunotherapy / checkpoint inhibitor treatment

Breast cancer · Patient profile

TNBC across all stages, including metastatic disease

Breast cancer · Patient profile

Breast cancer stages I–III

Breast cancer · Patient profile

Before or after CDK4/6 inhibitor treatment

Breast cancer · Patient profile

BRCA1/2- or PALB2-mutated, HR-positive / HER2-negative advanced disease

Breast cancer · Patient profile

ER-positive / HER2-negative advanced disease

Breast cancer · Patient profile

HER2-negative, BRCA-mutated neoadjuvant cohorts

Breast cancer · Patient profile

HER2-positive metastatic disease

Colorectal cancer · Patient profile

Metastatic disease with MSS, MSI-H, KRAS, NRAS or BRAF profiles

Colorectal cancer · Patient profile

Microsatellite-stable (MSS) colorectal cancer

Colorectal cancer · Patient profile

dMMR / MSI-H colon cancer

Colorectal cancer · Patient profile

dMMR / MSI-H rectal cancer

Colorectal cancer · Patient profile

Left-sided KRAS/NRAS/BRAF wild-type disease

Colorectal cancer · Patient profile

Second-line KRAS/NRAS/BRAF wild-type disease with prior chemotherapy

Gastric / GEJ cancer · Patient profile

CLDN18.2-expressing advanced or metastatic gastric/GEJ adenocarcinoma

Gastric / GEJ cancer · Patient profile

HER2-positive locally advanced or metastatic gastric/GEJ adenocarcinoma

Gastric / GEJ cancer · Patient profile

Late-stage or metastatic gastric adenocarcinoma

Ovarian cancer · Patient profile

BRCA wild-type or BRCA-mutated advanced disease

Ovarian cancer · Patient profile

HER2 IHC 3+, 2+ or 1+ advanced high-grade epithelial disease

Ovarian cancer · Patient profile

Platinum-resistant or platinum-sensitive disease

Ovarian cancer · Patient profile

Recurrent ovarian cancer

Prostate cancer · Patient profile

Metastatic prostate cancer

Prostate cancer · Patient profile

Metastatic castration-resistant prostate cancer (mCRPC)

Prostate cancer · Patient profile

mCRPC with prior taxane exposure

Prostate cancer · Patient profile

PSMA-positive mCRPC

Prostate cancer · Patient profile

Neuroendocrine prostate carcinoma

Bladder / urothelial cancer · Patient profile

Cisplatin-eligible or cisplatin-ineligible muscle-invasive disease

Bladder / urothelial cancer · Patient profile

Non-muscle-invasive bladder cancer

Endometrial cancer · Patient profile

B7-H4-expressing cohorts

Endometrial cancer · Patient profile

HER2 IHC 3+ or 2+ cohorts

Endometrial cancer · Patient profile

Mismatch repair-proficient (MMRp) disease

Endometrial cancer · Patient profile

Stage III/IV or recurrent disease

Pancreatic adenocarcinoma · Patient profile

Metastatic pancreatic ductal adenocarcinoma

Head & neck SCC · Patient profile

Platinum-eligible locally advanced HNSCC

Head & neck SCC · Patient profile

Metastatic HNSCC

Head & neck SCC · Patient profile

Before or after immunotherapy / checkpoint inhibitor treatment

Melanoma · Patient profile

Resectable stage III/IV melanoma

Melanoma · Patient profile

Before or after immunotherapy / checkpoint inhibitor treatment

Renal cell carcinoma · Patient profile

Stage III/IV or metastatic disease

Renal cell carcinoma · Patient profile

Clear-cell renal cell carcinoma (ccRCC)

Renal cell carcinoma · Patient profile

Before or after immunotherapy / checkpoint inhibitor treatment

Hepatocellular carcinoma · Patient profile

Adjuvant cohorts

Hepatocellular carcinoma · Patient profile

Neoadjuvant cohorts

Hepatocellular carcinoma · Patient profile

Stage III/IV or metastatic disease

Hepatocellular carcinoma · Patient profile

GPC3-positive hepatocellular carcinoma

Esophageal cancer · Patient profile

Advanced disease with longitudinal data

Small-cell lung cancer · Patient profile

Relapsed / refractory small-cell lung cancer

Small-cell lung cancer · Patient profile

Extensive-stage small-cell lung cancer

Neuroendocrine carcinoma · Patient profile

Poorly differentiated neuroendocrine carcinoma, including SCLC, large-cell neuroendocrine carcinoma (LCNEC) and extrapulmonary NEC

Non-Hodgkin lymphoma · Patient profile

Discuss the required subtype, tissue and associated data.

Cutaneous squamous cell carcinoma · Patient profile

Early-stage cutaneous squamous cell carcinoma

Cutaneous squamous cell carcinoma · Patient profile

Stage II–IV cutaneous squamous cell carcinoma

Glioblastoma · Patient profile

Recurrent glioblastoma (GBM)

Gastrointestinal stromal tumors · Patient profile

Gastrointestinal stromal tumors (GIST)

Build a cohort around your study

Share your indication, patient profile and required data. We’ll review tissue against your criteria.

Discuss your FFPE cohort

Discuss sample quantities, matching and available clinical data with our team.

SUPPORTING DATA & SERVICES

Molecularly characterized TMAs & FFPE blocks

Use recorded molecular findings to select cases, or add characterization to matched tissue. The examples below describe our characterization offering; coverage varies by case and assay.

NGS characterization: variants, copy number changes & fusions

DNA hotspots

EGFR · BRAF · ERBB2 · AKT1

Copy number changes

MET · ERBB2 · FGFR1 · PTEN

Fusions

ALK · ROS1 · RET · NTRK1

Explore 38 genes across 3 alteration types

DNA hotspot examples

  • AKT1
  • AKT2
  • AKT3
  • ALK
  • AR
  • ARAF
  • BRAF
  • CDK4
  • CDKN2A
  • CHEK2
  • CTNNB1
  • EGFR
  • ERBB2
  • ERBB3
  • ERBB4
  • ESR1
  • FGFR1
  • FGFR2
  • FGFR3
  • FGFR4
  • FLT3
  • GNA11
  • GNAQ
  • GNAS

Copy number changes

  • ALK
  • AR
  • CD274
  • CDKN2A
  • EGFR
  • ERBB2
  • ERBB3
  • FGFR1
  • FGFR2
  • FGFR3
  • KRAS
  • MET
  • PIK3CA
  • PTEN

Fusion examples

  • ALK
  • AR
  • BRAF
  • EGFR
  • ESR1
  • FGFR1
  • FGFR2
  • FGFR3
  • MET
  • NRG1
  • NTRK1
  • NTRK2
  • NTRK3
  • NUTM1
  • RET
  • ROS1
  • RSPO2
  • RSPO3

Additional targets for tissue characterization

Selected examples: HER2 · TROP2 · Nectin-4 · PD-L1 · Mesothelin

View all listed tissue targets
  • CD142 (TF)
  • AXL
  • EphA2
  • 5T4
  • LAMP1
  • CanAg
  • Integrin αv
  • HER3
  • Mesothelin
  • FGFR2
  • MET (HGFR)
  • Nectin-4
  • EGFR
  • c-KIT
  • HER2
  • EGFRvIII
  • CEACAM5
  • TROP2
  • PD-L1
  • CD3
  • CD8

Discuss the marker, tumor type and scoring requirements with our team. Existing results and any additional assay work are reviewed separately for the proposed cohort.

Assay controls

IHC control tissue: positive and negative FFPE control blocks

Choose IHC controls for antibody validation by the status of the marker your assay measures: a mutation, fusion or protein-expression target. Positive and negative control tissue is selected around your target. Control material is supplied as FFPE blocks. Tumor or normal tissue alone does not establish positive or negative status for that target.

Tell us the target and assay method, tissue type, required control status, format and quantity. Our team will review existing characterization and any additional screening needed.

  • EGFR exon 19 / 21 variants
  • KRAS G12A / C / D / V / R / S
  • ALK / RET / ROS1 fusions
  • PD-L1 / PD-1 expression

SUPPORTING DATA & SERVICES · MATCHED SAMPLES

Matched FFPE tissue & blood-based samples

Connect tissue findings with circulating biomarkers through collection-specific paired samples.

Matched samples

Tissue and blood from the same donor

Explore paired FFPE tissue and double-spun plasma or whole-blood collections across lung, colorectal, gastric, renal, esophageal, endometrial and ovarian cancers, and melanoma.

Explore plasma collections
Paired materials
FFPE tissue + double-spun plasma or whole blood
Collection source
Ukraine
Clinical context
This paired collection does not include outcome data.
Availability
Request current sets, volumes and collection details for your study.

SUPPORTING DATA & SERVICES · IMAGES

Whole-slide images linked to tissue and clinical data

Connect tissue morphology to clinical context. Explore H&E whole-slide images with matched archived FFPE tissue and anonymized donor records for computational pathology and translational research.

Scanned in house on Aperio GT450 and AT2 scanners at 40×, with .svs files and review of slides and images by medical pathologists.

Explore Image & Clinical Data
Representative H&E section of colon adenocarcinoma
H&E · Representative tumor tissue. Matched archived tissue can support further testing, subject to availability.

Assays & pathology support

Integrated tissue assay services

Pair selected FFPE tissue and TMAs with assays and pathology guidance, planned around your study.

Protein expression

IHC assay services

Add protein-expression measurements with 100+ optimized IHC assays, or discuss assay development for a new target.

Explore IHC services

Spatial RNA expression

RNAscope RNA-ISH

Localize target RNA in FFPE tissue, with pre-qualified samples, assay controls and pathologist scoring.

Explore RNAscope

Multiplex protein imaging

Multiplex immunofluorescence

Study protein co-expression, cell phenotypes and spatial relationships in selected FFPE tissue and TMAs.

Explore multiplex IF

100+ optimized IHC assays

Selected targets from the IHC library. Multiplex panels are reviewed separately.

Browse the IHC target library →

Growth factor signaling

Add IHC or RNAscope to this inquiry, and we'll plan the staining around your tissue. Request staining when you submit your tissue inquiry.

IHC staining on Ventana and Dako platforms. Review and scoring by medical pathologists with pharmaceutical industry experience.

Work with our experienced scientific team to tailor biospecimens, data, and integrated services to your research needs.

Our approach begins with our customers’ science.

We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.

Scientist working with a pipette in a laboratory

Plan your study

Tell us the FFPE cohort your study needs

Share your indication, stage, treatment and biomarker criteria, number of cases, specimen format and required data. We’ll review the available tissue and cohort options with you.

Request an FFPE cohort